MaaT Pharma
@MaaT_Pharma
Followers
2K
Following
3K
Media
1K
Statuses
3K
Our mission is to develop #microbiome-based therapies targeting mortality and comorbidities associated with cancer treatments.
Lyon, France
Joined September 2015
📰 [#PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease have been selected for oral presentation at American Society of Hematology (@ASH_hematology) Congress 2025. Key highlights: ✅ Oral
0
2
6
📰 [#Media] – MaaT Pharma featured in Drug Discovery World @DDWJournal for promising preclinical results of our anti-tumor microbiotherapy MaaT034! Thank you to Bruno Quinney for highlighting this important milestone in our mission to transform cancer treatment with
0
0
1
📅 [#Evènement] – Rencontrez le management de MaaT Pharma lors de la 7ème édition du Salon @InvestirDay : Eric Soyer, Chief Financial Officer, et Carole Schwintner, Chief Technology Officer, seront présents sur le stand L36, le 25 novembre 2025 ! 🦠Eric Soyer prendra la parole
0
1
2
MaaTÂ Pharma releases positive results for anti-tumour candidate https://t.co/kUcawZncnl Follow DDW; Business insights for the global scientific community #CancerResearch
1
3
5
📰 [#PressRelease] - MaaT Pharma announces the successful completion of its Global Offering of €9.1 million 👉 Read the press release: https://t.co/5neqbEltlm
0
0
2
📰 [#CommuniquéDePresse] - MaaT Pharma annonce le succès de son Offre Globale de 9,1 millions d’euros 👉 Pour en savoir plus, lire le communiqué de presse : https://t.co/fH2VSKb686
0
1
3
📰 [#PressRelease] – MaaT Pharma Launches a Capital Increase of Approximately €9 Million 👉 Read the press release: https://t.co/3U3SKhKAlJ
0
0
0
📰 [#CommuniquéDePresse] – MaaT Pharma lance une augmentation de capital d’un montant d’environ 9 millions d’euros 👉En savoir plus, lire le communiqué de presse : https://t.co/yPULcwBz34
0
0
0
📰 [#CommuniquéDePresse] – MaaT Pharma annonce la présentation de données précliniques actualisées au congrès SITC (@sitcancer) 2025. Nous sommes fiers de présenter des résultats prometteurs pour MaaT034, notre candidat-médicament microbiote de nouvelle génération, démontrant une
0
0
1
📰[#PressRelease] – MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer) 2025. We’re excited to share promising updated results for MaaT034, our next-gen microbiome therapy candidate, showing immune activation and anti-tumor activity in germ-free models. 💊
0
3
5
📄 [#CommuniquéDePresse] – MaaT Pharma publie ses résultats financiers du troisième trimestre 2025 et fait le point sur son financement ✅Paiement initial de 10,5 M€ reçu suite à la signature d’un accord exclusif de licence et de distribution avec Clinigen, ouvrant la voie à un
0
0
3
📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update ✅€10.5M upfront payment received from our exclusive license & distribution agreement with Clinigen, paving the way for potential European access to Xervyteg®
0
2
3
📰[#CommuniquéDePresse] – Nous sommes ravis d’annoncer la sélection des résultats de notre étude de Phase 3 évaluant Xervyteg® (MaaT013) dans la maladie aiguë du greffon contre l’hôte pour une présentation orale au Congrès 2025 de l’American Society of Hematology
0
1
5
📢 We’re proud to see our lead drug candidate, MaaT013, highlighted in the review “Deciphering and harnessing gut microbiota–associated immune regulation in acute graft-versus-host disease” by Emmanuelle Godefroy and Frédéric Altare, published in Current Opinion in Immunology.
0
2
4
📢 [#SITC2025] – Meet Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, during the 40th Anniversary Annual Meeting of the SITC - Society for Immunotherapy of Cancer (@sitcancer) in National Harbor, Maryland, USA. 🔬 On Friday, November 7, during the Microbiota and IO
0
3
6
Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (aGvHD) in Current Opinion in Immunology. The review article, titled “Emerging novel therapies for steroid-refractory acute graft-versus-host
0
2
5